June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Sight threatening complications in Sickle Cell Retinopathy
Author Affiliations & Notes
  • Gabriella De Salvo
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Pearse Keane
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Dawn Sim
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Catherine Egan
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships Gabriella De Salvo, None; Pearse Keane, None; Dawn Sim, None; Catherine Egan, Bayer (S), Oculogics (S), Novartis (S), Allergan (S), Novartis (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3846. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gabriella De Salvo, Pearse Keane, Dawn Sim, Catherine Egan; Sight threatening complications in Sickle Cell Retinopathy. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3846.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Sickle cell retinopathy (SCR) is a hemoglobinopathy that can present with mild to severe proliferative retinal findings. In this abstract we describe features of non-proliferative and proliferative SCR and sight threatening complications of this disorder.

Methods: Clinical and imaging data were retrospectively collected from patients attending medical retina clinics at Moorfields Eye Hospital. Color fundus photographs, Optical Coherence Tomography (OCT), Fluorescein angiography (FA) and health records were reviewed. Clinical features noted included: abnormalities of the vitreoretinal interface at the macula [vitreomacular traction (VMT), macular hole (MH), epiretinal membrane (ERM)] and features related to the proliferative retinopathy [vitreous hemorrhage (VH), tractional retinal detachment (TRD)]. Final visual outcome was collected.

Results: 260 eyes from 130 patients with SCR were reviewed retrospectively. 24 eyes (9.23%) had no apparent ocular disease. Complications of the vitreoretinal interface were seen in 77 eyes: 29.62% (TRD 18.85%, MH 5.38%, VMT 1.54%, ERM 3.85%). A total of 66 eyes (25.4%) underwent one or more vitreoretinal procedures (12.7% for TRD, 3.5% for MH, 8.1% for VH). The final visual outcome was as follows: 80% had a visual acuity (VA) equal or better than 6/12, while 20% had a final VA equal or worse than 6/18 [No light perception in 4 eyes (1.54%), light perception in 4 (1.54%), hand motion in 5 (1.92%), count fingers in 3 (1.15%), and 36 eyes (13.85%) had VA between 6/18 to 6/60].

Conclusions: SCR, both non-proliferative and proliferative disease, can present with sight threatening complications. A higher than expected number of patients had significant visual loss from abnormalities of the vitreoretinal interface at the macula or related to proliferative disease that ultimately required surgical intervention.

Keywords: 688 retina • 550 imaging/image analysis: clinical  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×